ZNF385D Antibody

What is ZNF385D and what are its known functions?

ZNF385D (Zinc Finger Protein 385D) is a transcription factor with functions related to nucleic acid binding and zinc ion binding . Recent research has revealed its potential role in several pathological processes. ZNF385D has been implicated in the development of carotid atherosclerosis, with studies demonstrating its involvement in transcriptional regulatory networks affecting atheroma plaque formation . Additionally, variations in the ZNF385D gene (rs13070110) have been associated with an increased risk of intracerebral hemorrhage . The protein may also influence negative symptoms of schizophrenia, and its elevated expression has been linked to anxiety and depressive symptoms in patients with chronic obstructive pulmonary disease . As a transcription factor, ZNF385D regulates a large network of genes (5644 target genes identified in one study), with 3078 genes positively regulated and 2566 genes negatively regulated .

What types of ZNF385D antibodies are available for research purposes?

Various ZNF385D antibodies are available for research applications, differing in their binding specificity, host organism, clonality, and validated applications:

Multiple variants targeting different epitopes allow researchers to select antibodies based on specific experimental requirements and target species .

What are the optimal dilution ratios for different applications of ZNF385D antibodies?

The optimal dilution ratios for ZNF385D antibodies vary depending on the specific antibody and application. Based on the available data:

It's important to note that these are general recommendations, and optimization may be necessary for specific experimental conditions. Researchers should perform titration experiments to determine the optimal antibody concentration for their specific sample type and detection method .

How should researchers optimize ZNF385D antibody protocols for different tissue or cell types?

Optimization of ZNF385D antibody protocols should consider several factors:

• Sample type consideration: Different tissues express ZNF385D at varying levels. Validated reactivity has been confirmed in mouse kidney tissue and human testis tissue , but expression may differ in other tissues.

• Protocol adjustments:

  • For Western Blot: Optimize protein extraction methods based on tissue type. For tissues with high fat content or fibrous structure, specialized lysis buffers may be required.

  • For IHC: Antigen retrieval methods may need optimization (heat-induced vs. enzymatic retrieval) depending on tissue fixation.

• Blocking optimization: Use 5-10% normal serum from the same species as the secondary antibody to reduce background.

• Validation controls: Include positive control tissues (e.g., kidney or testis) and negative controls (omitting primary antibody) to ensure specificity .

• Signal enhancement: For tissues with low ZNF385D expression, consider using signal amplification systems like tyramide signal amplification (TSA) for IHC applications.

Each new tissue or cell type may require protocol adjustments to achieve optimal signal-to-noise ratio.

What storage conditions are recommended for maintaining ZNF385D antibody activity?

To maintain optimal activity of ZNF385D antibodies, the following storage conditions are recommended:

Always return antibodies to the recommended storage conditions promptly after use and avoid contamination to maintain long-term stability and performance.

How can researchers validate the specificity of ZNF385D antibodies in their experimental system?

Validating ZNF385D antibody specificity is critical for experimental reliability. A comprehensive validation approach should include:

• Positive and negative controls:

  • Use tissues known to express ZNF385D (e.g., mouse kidney, human testis) as positive controls

  • Include tissues from ZNF385D knockout models or tissues known not to express the protein as negative controls

• Blocking peptide competition:

  • Perform parallel experiments with and without pre-incubation of the antibody with a ZNF385D blocking peptide

  • The specific signal should be significantly reduced or eliminated in the presence of the blocking peptide

• Multiple antibody validation:

  • Use antibodies targeting different epitopes of ZNF385D (e.g., N-terminal and C-terminal antibodies)

  • Concordant results across different antibodies increase confidence in specificity

• siRNA knockdown:

  • Reduce endogenous ZNF385D expression using siRNA in cell culture

  • Compare antibody signal between control and knockdown samples; specific antibodies should show reduced signal in knockdown samples

• Mass spectrometry confirmation:

  • For advanced validation, immunoprecipitate ZNF385D and confirm its identity by mass spectrometry

Documentation of these validation steps is essential for publication and ensures experimental reproducibility.

What are the advantages and limitations of different detection methods for ZNF385D?

Different detection methods offer various advantages and limitations for ZNF385D research:

When selecting a detection method, researchers should consider their specific experimental questions, available samples, and required sensitivity/specificity balance.

How can ZNF385D antibodies be used for studying its role in transcriptional regulation networks?

ZNF385D functions as a transcription factor with an extensive regulatory network. To study its role in transcriptional regulation:

• Chromatin Immunoprecipitation (ChIP):

  • Use ZNF385D antibodies for ChIP followed by sequencing (ChIP-seq) to identify genome-wide binding sites

  • Validate binding sites with ChIP-qPCR for specific target genes

  • Compare binding patterns in normal vs. disease states (e.g., atherosclerotic vs. normal vascular tissue)

• Co-Immunoprecipitation (Co-IP):

  • Identify protein-protein interactions between ZNF385D and other transcriptional regulators

  • Use antibodies for immunoprecipitation followed by mass spectrometry or western blotting

• Dual-luciferase reporter assays:

  • Assess the functional effects of ZNF385D on promoter activity of potential target genes

  • Compare wild-type ZNF385D with mutant variants to analyze structure-function relationships

• Integration with gene expression data:

  • Combine ChIP-seq with RNA-seq after ZNF385D modulation (overexpression/knockdown)

  • Identify directly regulated genes through integrated analysis

  • Analyze the regulatory network similar to the study identifying 5644 target genes (3078 positively and 2566 negatively regulated)

• Network analysis:

  • Use tools like Gene Set Enrichment Analysis (GSEA) to identify pathways regulated by ZNF385D

  • Calculate enrichment scores for positive and negative regulation as demonstrated in previous research (ES positive = -0.9, ES negative = 0.91)

These approaches, using validated ZNF385D antibodies, can provide comprehensive insights into its transcriptional regulatory functions in both normal physiology and disease states.

What are common issues encountered when using ZNF385D antibodies and how can they be resolved?

Researchers commonly encounter several issues when working with ZNF385D antibodies. Here are solutions for the most frequent problems:

• High background in Western blot:

  • Increase blocking time/concentration (5% non-fat milk or BSA)

  • Optimize primary antibody dilution (start with manufacturer recommendations, e.g., 1:500-1:1000)

  • Increase washing duration and number of washes

  • Reduce secondary antibody concentration

  • Use fresh blocking reagents and buffers

• Weak or no signal in Western blot:

  • Verify sample expression of ZNF385D (use positive control tissues like kidney or testis)

  • Reduce antibody dilution (use more concentrated antibody)

  • Increase protein loading amount

  • Optimize exposure time

  • Ensure proper transfer efficiency

  • Check protein extraction method is appropriate for nuclear proteins

• Non-specific bands:

  • Verify expected molecular weight (42 kDa for ZNF385D)

  • Increase antibody dilution

  • Use gradient gels for better separation

  • Perform peptide competition assay to identify specific bands

  • Consider alternative antibody targeting different epitope

• Poor IHC staining:

  • Optimize antigen retrieval methods

  • Adjust antibody concentration (try 1:20-1:50 for IHC-P)

  • Increase antibody incubation time (overnight at 4°C)

  • Ensure tissue fixation was appropriate

  • Use detection systems with signal amplification

• Inconsistent results between experiments:

  • Standardize all protocol parameters

  • Use the same lot of antibody when possible

  • Prepare master mixes for reagents

  • Include consistent positive controls

  • Document all experimental conditions meticulously

Methodical troubleshooting with careful documentation of all protocol modifications will help identify optimal conditions for ZNF385D detection.

How should researchers interpret variations in ZNF385D expression levels across different tissue types?

When interpreting variations in ZNF385D expression across tissues, researchers should consider several factors:

• Establish baseline expression profiles:

  • Compare expression with reference databases (e.g., Human Protein Atlas, GTEx)

  • Documented expression has been observed in kidney and testis tissues

  • Use consistent detection methods and quantification approaches

• Biological interpretation of variations:

  • Consider tissue-specific transcriptional programs

  • Evaluate correlation with known ZNF385D-regulated pathways (e.g., immune response to inflammation in atherosclerosis)

  • Assess relationship to tissue-specific functions and disease states

• Technical considerations for accurate quantification:

  • Normalize to appropriate housekeeping genes/proteins that are stable across compared tissues

  • Use multiple detection methods (e.g., WB, qPCR, IHC) to confirm expression patterns

  • Consider relative expression rather than absolute values when comparing across tissue types

• Pathological significance assessment:

  • Compare normal vs. diseased tissue from the same origin

  • Note that ZNF385D was found downregulated in atherosclerotic tissue (logFC = -0.14, p = 1.88 × 10-6)

  • Evaluate correlation with disease markers or clinical parameters

• Statistical robustness:

  • Apply appropriate statistical tests for multiple tissue comparisons

  • Account for individual variations and sample size limitations

  • Consider fold-change thresholds alongside statistical significance

Understanding both the biological context and technical limitations is essential for meaningful interpretation of ZNF385D expression differences across tissues.

What statistical approaches are recommended for analyzing ZNF385D expression data in disease studies?

For robust analysis of ZNF385D expression in disease studies, the following statistical approaches are recommended:

These statistical methods should be selected based on study design, sample size, and specific research questions while ensuring appropriate validation through techniques such as cross-validation or bootstrap resampling.

How can ZNF385D antibodies be utilized to study its role in atherosclerosis and vascular diseases?

ZNF385D has emerging significance in atherosclerosis research, with antibodies playing a crucial role in elucidating its functions:

• Tissue-specific expression profiling:

  • Use immunohistochemistry with antibodies like NBP1-82121 (1:20-1:50 dilution) to compare ZNF385D expression between:

    • Atherosclerotic plaque vs. healthy vascular tissue

    • Different stages of atherosclerotic progression

    • Various vascular beds (carotid, coronary, peripheral)

• Mechanistic investigations:

  • Apply Western blot (Proteintech 20806-1-AP, 1:500-1:1000) to quantify expression changes in:

    • In vitro models of endothelial dysfunction

    • Vascular smooth muscle cell proliferation/migration studies

    • Inflammatory stimulation of vascular cells

• Transcriptional network analysis:

  • Combine ChIP-seq and RNA-seq to identify direct ZNF385D targets in vascular tissues

  • Focus on the previously identified regulatory network (5644 target genes)

  • Analyze differentially regulated pathways between atherosclerotic and normal tissues

• Clinical correlation studies:

  • Correlate ZNF385D expression with:

    • Carotid intima-media thickness (CIMT) measurements

    • Plaque vulnerability characteristics

    • Inflammatory markers in patient samples

• Functional studies in atherosclerosis models:

  • Monitor ZNF385D expression changes during:

    • Induced atherosclerosis in animal models

    • Therapeutic interventions targeting inflammation

    • Regression of established plaques

Recent research has demonstrated that ZNF385D is downregulated in atherosclerotic tissues (logFC = -0.14, p = 1.88 × 10-6) with extremely significant enrichment of its target genes in the atherosclerosis phenotype (p < 2.26 × 10-308) , suggesting its potential as both a biomarker and therapeutic target.

What approaches can be used to study the interplay between ZNF385D and other transcription factors in disease contexts?

Investigating the interplay between ZNF385D and other transcription factors requires sophisticated methodological approaches:

• Co-immunoprecipitation (Co-IP) and protein interaction studies:

  • Use ZNF385D antibodies to pull down protein complexes

  • Identify interaction partners through mass spectrometry

  • Confirm specific interactions with other transcription factors (e.g., HAND2) through reciprocal Co-IP

  • Map interaction domains through deletion mutants

• Sequential ChIP (ChIP-reChIP):

  • Perform ChIP with ZNF385D antibody followed by secondary ChIP with antibodies against other transcription factors

  • Identify genomic regions co-occupied by ZNF385D and other factors

  • Compare co-occupancy patterns between normal and disease states

• Proximity ligation assay (PLA):

  • Visualize and quantify interactions between ZNF385D and other transcription factors at single-molecule resolution

  • Analyze spatial distribution of interactions within nuclear subcompartments

  • Compare interaction frequencies between different cell types or disease states

• CRISPR-based approaches:

  • Generate single or double knockout models of ZNF385D and interacting transcription factors

  • Perform epistasis analysis to determine functional relationships

  • Use CRISPRa/CRISPRi to modulate expression levels and assess compensatory mechanisms

• Integrative network analysis:

  • Compare regulatory networks of ZNF385D (5644 target genes) and other transcription factors like HAND2 (781 target genes)

  • Identify network overlap, synergy, or antagonism

  • Apply mathematical modeling to predict emergent properties of interacting networks

The significant involvement of both ZNF385D and HAND2 in atherosclerosis (p < 6.95 × 10-7) suggests that studying their cooperative or competitive regulation could reveal important disease mechanisms and therapeutic opportunities.

How can researchers investigate the potential role of ZNF385D in neurological disorders and mental health conditions?

Recent research has implicated ZNF385D in several neurological and psychiatric conditions. To investigate these associations, researchers can employ the following approaches:

• Expression profiling in neural tissues and models:

  • Use Western blot (1:500-1:1000 dilution) to quantify ZNF385D expression in:

    • Post-mortem brain tissue from patients with schizophrenia, anxiety, or depression

    • Neural cell types (neurons, astrocytes, microglia) derived from iPSCs

    • Animal models of neuropsychiatric disorders

• Genetic association validation:

  • Correlate ZNF385D expression with specific polymorphisms (e.g., variants associated with schizophrenia)

  • Perform functional studies of disease-associated variants

  • Use CRISPR-Cas9 to introduce specific mutations and assess phenotypic consequences

• Neuronal function studies:

  • Investigate effects of ZNF385D modulation on:

    • Neuronal morphology and connectivity

    • Electrophysiological properties

    • Neurotransmitter release and reception

    • Synaptic plasticity mechanisms

• Behavioral phenotyping:

  • Generate conditional ZNF385D knockout or overexpression models

  • Assess behaviors relevant to:

    • Anxiety and depression-like symptoms (previously associated with elevated ZNF385D expression)

    • Cognitive functions affected in schizophrenia

    • Stress responses related to COPD comorbidity

• Cellular pathway analysis:

  • Identify neural-specific targets within the ZNF385D regulon

  • Focus on pathways involved in:

    • Neuroinflammation (potentially linking to its role in inflammation in atherosclerosis)

    • Neurodevelopmental processes

    • Stress response mechanisms

• Therapeutic target assessment:

  • Screen for compounds that modulate ZNF385D expression or activity

  • Evaluate effects on neural cell function and related molecular pathways

  • Assess potential for repurposing existing drugs that affect ZNF385D pathways

These multidisciplinary approaches can help elucidate the mechanisms by which ZNF385D influences neurological and psychiatric conditions, potentially identifying new therapeutic strategies for these complex disorders.

What are the most promising future directions for ZNF385D research using antibody-based approaches?

Based on current knowledge and emerging findings, several promising research directions for ZNF385D utilizing antibody-based methodologies include:

• Single-cell analysis of ZNF385D expression and function:

  • Apply antibodies optimized for flow cytometry or mass cytometry to analyze ZNF385D at single-cell resolution

  • Combine with other markers to identify cell-specific roles in heterogeneous tissues

  • Integrate with single-cell transcriptomics to map cell-type specific regulatory networks

• Advanced spatial biology approaches:

  • Employ multiplexed immunofluorescence to study ZNF385D co-localization with interacting partners

  • Apply spatial transcriptomics with protein detection to map ZNF385D activity across tissue microenvironments

  • Use high-resolution imaging techniques to analyze nuclear distribution and chromatin association

• Liquid biopsy development:

  • Explore ZNF385D as a circulating biomarker for conditions like atherosclerosis or neurological disorders

  • Develop sensitive immunoassays for detection in blood or other biofluids

  • Correlate with disease progression and treatment response

• Therapeutic modulation monitoring:

  • Use antibodies to assess pharmacodynamic responses to drugs targeting ZNF385D regulatory pathways

  • Monitor changes in ZNF385D expression or localization during disease progression and treatment

  • Develop companion diagnostics for emerging therapeutics

• Multi-omics integration:

  • Combine antibody-based proteomics with genomics, transcriptomics, and epigenomics

  • Apply systems biology approaches to model ZNF385D's role in complex disease networks

  • Identify feedback loops and regulatory mechanisms controlling ZNF385D function

The significant enrichment of ZNF385D-regulated genes in disease phenotypes (p < 2.26 × 10-308) underscores its potential importance as both a biomarker and therapeutic target, particularly in cardiovascular and neurological disorders.

What methodological advances are needed to better understand ZNF385D's regulatory mechanisms in disease pathogenesis?

To advance understanding of ZNF385D's regulatory mechanisms in disease, several methodological improvements are needed:

• Enhanced antibody specificity and applications:

  • Development of antibodies with enhanced specificity for different ZNF385D isoforms

  • Antibodies validated for additional applications (ChIP-seq, CyTOF, super-resolution microscopy)

  • Phospho-specific antibodies to detect post-translational modifications affecting ZNF385D function

• Temporal dynamics analysis:

  • Live-cell imaging approaches using fluorescently tagged antibody fragments

  • Optogenetic tools to modulate ZNF385D activity with temporal precision

  • Time-resolved ChIP-seq to capture dynamic binding patterns

• Structural biology integration:

  • Epitope-specific antibodies targeting functional domains of ZNF385D

  • Methods to study conformational changes affecting DNA binding activity

  • Approaches to visualize ZNF385D-DNA-protein complexes in situ

• Improved disease models:

  • Patient-derived cellular models with preserved ZNF385D regulatory networks

  • Humanized animal models expressing human ZNF385D variants

  • Organoid systems to study tissue-specific functions in controlled environments

• Computational method development:

  • Enhanced algorithms for integrating ZNF385D binding data with gene expression

  • Machine learning approaches to predict context-specific regulatory effects

  • Network modeling tools to capture complex interactions within the regulon of 5644 target genes

• High-throughput functional assays:

  • CRISPR screens targeting ZNF385D binding sites in disease-relevant genes

  • Massively parallel reporter assays to characterize variant effects on ZNF385D binding

  • Barcoded overexpression/knockdown systems to assess dosage effects